Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

Blocking cholesterol biosynthesis pathway in cancer cells appears to improve ability of common drugs

Blocking cholesterol biosynthesis pathway in cancer cells appears to improve ability of common drugs

Personalized rectal cancer therapy shows promise

Personalized rectal cancer therapy shows promise

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

FDA approves KRAS gene mutation test for colorectal cancer

FDA approves KRAS gene mutation test for colorectal cancer

Study details canonical Wnt signaling pathway

Study details canonical Wnt signaling pathway

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex announces data from JX-594 clinical studies on cancer

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Study reveals why GBM is highly resistant to current chemotherapies

Study reveals why GBM is highly resistant to current chemotherapies

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

Aurora-A protein plays an important role in head and neck cancer

Aurora-A protein plays an important role in head and neck cancer

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Researchers test nanoscale carbon clusters for cancer chemotherapy

Researchers test nanoscale carbon clusters for cancer chemotherapy

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Study describes new pharmacological resistance to colon cancer

Study describes new pharmacological resistance to colon cancer

Erlotinib better for treatment of non-small cell lung cancers

Erlotinib better for treatment of non-small cell lung cancers